Anti-GLG1 antibody
Description
Application Data
Description
-
An antibody raised against E-selectin ligand-1 (ESL-1); also known as GLG1, it is a golgi apparatus-localized protein which acts in osteoblasts to regulate bone homeostasis.
Application Data
-
Material Safety Data Sheet (MSDS)Catalogue number crb2005619 Antibody Anti-GLG1 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200815e Protein ID Q92896 Human GLG1 Aliases Golgi apparatus protein 1, Cysteine-rich fibroblast growth factor receptor, CFR-1, E-selectin ligand 1, ESL-1, Golgi sialoglycoprotein MG-160, GLG1, CFR1, ESL1, MG160 Cross-Reactivity Human, Mouse, Rat Target Protein Species Human, Mouse, Rat Host Species Rabbit Antibody Type Polyclonal Concentration 1mg/ml Target GLG1 Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Post-translational Modification Fucosylation, N-glycosylated Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References Werneburg et al., (2016). Polysialylation and lipopolysaccharide-induced shedding of E-selectin ligand-1 and neuropilin-2 by microglia and THP-1 macrophages. Glia. 64(8): 1314. PMID: 27159043.
Yamamoto et al., (2016). E-selectin ligand-1 (ESL-1) is a novel adiponectin binding protein on cell adhesion. Biochem Biophys Res Commun. 470(2): 425. PMID: 26792720.
Yang et al., (2013). E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment. PNAS U.S.A. 110(18): 7336. PMID: 23589896.
ESL-1 as an important regulator of bone remodelling which localises to the Golgi apparatus. It functions to maintain a balanced bone homeostasis where it can play either a catabolic or anabolic role. ESL-1 regulates TGF-β maturation during cartilage homeostasis. ESL-1 is also a novel adiponectin (APN)-binding protein. APN is an adipocyte-derived bioactive molecule with anti-diabetic and anti-atherogenic properties. ESL-1 is also a novel polysialic acid (polySia) acceptor. PolySia is a protein-modifying glycan implicated in modulating microglia activity.
GLG1 acts in the initial process to tether leukocytes to vascular endothelium however, this role has been implicated in the method tumour cells are able to progress and migrate. GLG1 has also been linked to the Lou Gehrig’s disease also known as Amyotrophic Lateral Sclerosis 1 (ALS1).